Expiration date: 03/2025

The composition and form of issue:

Tablets. 1 tablet contains glucosaminilmuramilpentapeptide (GMDP) 1 or 10 mg

excipients: lactose sucrose starch cellulose calcium stearate 

in a contour acheikova packing 10 PCs. in cardboard pack 1 or 2 packs.

Description pharmaceutical form:

Round white pill with a chamfer. Tablets 10 mg are at risk.

Pharmacokinetics:

Drug bioavailability after oral administration is 7-13%. The degree of binding to albumin of the blood is weak. Active metabolites not formed. Tmax of 1.5 h, T1/2 — 4,29 h. Excreted unchanged, mainly through the kidneys.

Description pharmacological action:

The biological activity of the drug due to the presence of specific binding (receptors) to GMDP localized in endoplasmic phagocytes and T-lymphocytes. The drug stimulates the functional (bactericidal, cytotoxic) activity of phagocytes (neutrophils, macrophages), enhances proliferation of T - and b-lymphocytes, increases the synthesis of specific antibodies. The pharmacological action is carried out by enhancing the production of interleukins (IL-1, IL-6, IL-12), tumor necrosis factor-alpha, interferon-gamma, colony stimulating factors. The drug increases the activity of natural killer cells.

Dosage:

Usage INSTRUCTIONS

ENDORSED by the FC of the RF MOH, 24.12.1998, St. No. 13.

Description. White round pill with no shell.

The pharmacological properties. The drug has immunomodulatory properties. With secondary immunodeficiencies in doses of 1-10 mg increases the activity of phagocytes (macrophages and neutrophils), T - and B-lymphocytes. This increases bactericidal and cytotoxic activity of phagocytes, and stimulates the synthesis of specific antibodies and cytokines (interleukins, tumor necrosis factor, interferons and colony stimulating factors). Licopid application in complex therapy allows to significantly increase the efficiency of antibacterial, antifungal and antiviral therapy, reducing the duration of treatment and significantly reduce the dose of chemotherapeutic agents.

In autoimmune diseases in doses above 20 mg Licopid inhibits the biosynthesis of anti-inflammatory cytokines.

Indications. Licopid used in adults and children in complex therapy of secondary immunodeficiencies, manifested as chronic, smoldering, recurrent infectious-inflammatory processes of any localization.

Licopid (tablets at 1 and 10 mg) are shown in the framework of complex therapy in adults:

• in chronic infections of the upper and lower respiratory tract for the treatment of relapse and relapse prevention
  
• in acute and chronic purulent-inflammatory diseases of the skin and soft tissues, including treatment and prevention of purulent-septic postoperative complications
  
• tuberculosis
  
• when eye herpes
  
• when lesions of the cervix with human papillomavirus
  
• all forms of psoriasis.
  

Licopid (tablet 1 mg) are shown in the framework of complex therapy in children:

 for treatment of acute and chronic purulent-inflammatory diseases of the skin and soft tissues

• when herpetic infections of any location
  
• in chronic viral hepatitis B and C.
  

Method of application and doses. In adults. Licopid used for 30 minutes before eating orally (tablets of 10 mg) or sublingually (tablets of 1 mg).

Infections upper and lower respiratory tract in the acute stage Licopid appoint 1-2 mg under the tongue 1 time a day for 10 days. For the prevention of exacerbations of chronic respiratory tract infections with a protracted, often relapsing Licopid appoint 5-10 mg 1 time per day for 10 days.

For the prevention of postoperative complications Licopid appoint 1-2 mg under the tongue 1 time a day for 5-10 days. For the treatment of purulent-septic processes of the skin and soft tissues, including postoperative, moderate Licopid administered at a dose of 2 mg under the tongue 2-3 times a day for 10 days. In severe purulent-septic processes Licopid designate the interior of 10 mg 1 time per day for 10 days.

In pulmonary tuberculosis Licopid appoint 10 mg 1 times a day orally for 10 days.

When eye herpes Licopid administered orally at a dose of 10 mg 2 times a day for 3 days. After a break of 3 days, repeat the treatment.

When lesions of the cervix with human papillomavirus Licopid administered at a dose of 10 mg orally 1 time a day for 10 days.

For the treatment of psoriasis Licopid appoint: at a moderate incidence of rash oral dose of 10 mg 1-2 times a day for 10 days and then within the next 10 days at 10-20 mg a day when a large area of destruction — 10 mg orally 2 times a day for 20 days.

In children. In children aged 1-16 years Licopid used only in the form of tablets of 1 mg.

In the treatment of chronic respiratory tract infections and purulent skin infections in children aged 1-6 years Licopid administered orally at a dose of 1 mg 1 time a day for 10 days.

In the treatment of herpes infections of all sites in children aged 1-16 years Licopid administered orally at a dose of 1 mg 3 times a day for 10 days.

In the treatment of chronic viral hepatitis B and C in children aged 1-16 years Licopid administered orally at a dose of 1 mg 3 times a day for 20 days.

In the case of persistent currents infectious diseases (pneumonia, bronchitis, enterocolitis, sepsis, postoperative complications, etc.) in newborns Licopid administered orally at a dose of 0.5 mg 2 times a day for 7-10 days.

Side effects. In some cases, there is moderate rise in temperature (up to 37.9 °C).

Contraindications. Pregnancy, individual intolerance of the drug.

Form of issue. Tablets of 1 and 10 mg, in a contour acheikova packing 10 PCs., in a cardboard bundle 1 package.

The storage conditions. In a cool, dry, dark place. List B.

Conditions of supply of pharmacies. With a doctor's prescription.

Manufacturer. CJSC "Peptek".

Indications:

Complex therapy of conditions involving secondary immunodeficiencies in adults and children.

Adults (tablets 1 and 10 mg):

• chronic infection of the lungs
  
• acute and chronic purulent-inflammatory diseases of the skin and soft tissues, including purulent-septic postoperative complications
  
• herpes infection (i.e. eye herpes)
  
• human papillomavirus infection
  
• psoriasis (including arthropathic form)
  
• tuberculosis of the lungs.
  

Children (only tablets 1 mg):

• acute and chronic purulent-inflammatory diseases of the skin and soft tissues
  
• chronic infection of the upper and lower respiratory tract in the acute stage and in remission
  
• herpetic infection of any localization
  
• chronic viral hepatitis b and C.
  

Contraindications:

• individual hypersensitivity to the drug
  
• pregnancy
  
• lactation
  
• autoimmune thyroiditis in the acute phase
  
• States in diseases, accompanied by high fever or hyperthermia (>38 °C).
  

Application of pregnancy and breast-feeding:

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects:

At the beginning of treatment may be short-term increase body temperature (not above 37,9 °C), which is not the indication to cancellation of the drug. Other side effects during treatment of Licopid not revealed.

Drug interactions:

The drug increases the effectiveness of semisynthetic penicillins, fluoroquinolones, cephalosporins, polyene derivatives. It is noted synergies in relation to antiviral and antifungal drugs. Antacids and adsorbents can significantly reduce the bioavailability of the drug. Corticosteroids reduce the biological effect of Licopid. Inappropriate joint appointment Licopid with sulfa drugs, tetracyclines.

Method of application and dose:

Adults

Sublingual (under the tongue) and inside, erh, 30 minutes before a meal.

For prophylaxis of postoperative complications appoint Licopid 1 mg sublingually 1 time per day for 10 days.

For the treatment of purulent-septic lesions of the skin and soft tissues, moderate, including postoperative — 2 mg sublingually 2-3 times a day for 10 days.

In the treatment of severe purulent-septic processes, and 10 mg orally 1 time a day for 10 days.

Chronic lung infections — 1-2 mg sublingually 1 time per day for 10 days.

In pulmonary tuberculosis, and 10 mg of 1 times a day sublingually for 10 days.

If you have a herpes infection in the form of light — 2 mg 1-2 times a day sublingually for 6 days in severe forms — 10 mg 1-2 times a day sublingually for 6 days.

When eye herpes — orally 10 mg 2 times a day for 3 days. After a 3-day break, repeat the treatment.

When lesions of the cervix with human papillomavirus — 10 mg orally 1 time a day for 10 days.

Psoriasis — 10-20 mg orally 1-2 times a day for 10 days and on through the day, 10-20 mg for the next 10 days. When severe and extensive lesions (including arthropathic form) — 10 mg 2 times a day for 20 days.

Children

Infants with protracted course of infectious diseases (pneumonia, bronchitis, enterocolitis, sepsis, postoperative complications, etc.) to 0.5 mg orally 2 times a day for 7-10 days.

Children aged 1-16 years Licopid only in the form of tablets of 1 mg.

In the treatment of chronic infections of the respiratory tract and purulent infections of the skin, and 1 mg orally 1 time a day for 10 days.

In the treatment of herpetic infection (regardless of localization) and 1 mg 3 times a day orally for 10 days.

In the treatment of chronic viral hepatitis b and C — 1 mg orally 3 times a day for 20 days.

Overdose:

Cases overdose unknown.

Special instructions:

Does not affect the ability to drive and use heavy machinery.